Zomedica Pharmaceuticals Corp (ZOM) — Cash Flow-to-Debt Ratio
Zomedica Pharmaceuticals Corp (ZOM) has a Cash Flow-to-Debt Ratio of -0.63x as of March 2025, meaning its operating cash flow of $-6.65 Million could theoretically repay -1% of its total liabilities ($10.55 Million) in one year. See ZOM free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zomedica Pharmaceuticals Corp Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Zomedica Pharmaceuticals Corp across 12 annual periods. Also explore how fast is Zomedica Pharmaceuticals Corp growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Zomedica Pharmaceuticals Corp (2013–2024)
Year-by-year debt coverage analysis for Zomedica Pharmaceuticals Corp. For market capitalisation and broader financial context, see Zomedica Pharmaceuticals Corp market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.02x | $-23.63 Million | $11.70 Million | ▼ -66.7% |
| 2023 | -1.21x | $-15.97 Million | $13.18 Million | ▼ -26.9% |
| 2022 | -0.96x | $-11.67 Million | $12.22 Million | ▲ +36.3% |
| 2021 | -1.50x | $-14.28 Million | $9.51 Million | ▼ -39.3% |
| 2020 | -1.08x | $-16.24 Million | $15.08 Million | ▲ +85.6% |
| 2019 | -7.49x | $-15.63 Million | $2.09 Million | ▼ -59.7% |
| 2018 | -4.69x | $-11.15 Million | $2.38 Million | ▲ +45.2% |
| 2017 | -8.56x | $-7.09 Million | $828.74K | ▼ -39.0% |
| 2016 | -6.16x | $-4.56 Million | $741.16K | ▼ -1705.1% |
| 2015 | -0.34x | $-49.88K | $146.29K | ▲ +96.8% |
| 2014 | -10.54x | $-41.44K | $3.93K | ▲ +12.6% |
| 2013 | -12.06x | $-62.19K | $5.16K | — |